Neurogene (NGNE) Assets Average (2014 - 2026)
Neurogene's (NGNE) quarterly Assets Average came in at $275.9 million in Q1 2026, down 15.25% YoY from $325.5 million in Q1 2025, and down 4.28% on a QoQ basis from $288.2 million in Q4 2025.
Neurogene (NGNE) Assets Average (2014 - 2026) Analysis & Trends
Neurogene (NGNE) has 13 years of Assets Average data on file, last reported at $275.9 million in Q1 2026.
- Quarterly Assets Average fell 15.25% year-over-year to $275.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $275.9 million (down 15.25% YoY) and the FY2025 annual result came in at $312.2 million, up 11.83% from the prior year.
- Assets Average eased to $275.9 million in Q1 2026, from $288.2 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $325.5 million in Q1 2025 to a low of $91.8 million in Q3 2023.
- A 5-year average of $194.3 million and a median of $172.0 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average slumped 33.5% — and 2024, when it jumped 101.19%.
- Tracing NGNE's Assets Average over 5 years: stood at $117.9 million in 2022, then jumped by 32.36% to $156.1 million in 2023, then soared by 60.13% to $249.9 million in 2024, then rose by 15.32% to $288.2 million in 2025, then slipped by 4.28% to $275.9 million in 2026.
- The last three Assets Average figures came in at $275.9 million (Q1 2026), $288.2 million (Q4 2025), and $292.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | 253.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 253.75 Mn |
| Mar 31, 2026 | 275.87 Mn |
| Dec 31, 2025 | 288.22 Mn |
| Sep 30, 2025 | 292.57 Mn |
| Jun 30, 2025 | 306.31 Mn |
| Mar 31, 2025 | 325.52 Mn |
| Dec 31, 2024 | 249.93 Mn |
| Sep 30, 2024 | 171.97 Mn |
| Jun 30, 2024 | 187.59 Mn |
| Mar 31, 2024 | 208.96 Mn |
| Dec 31, 2023 | 156.08 Mn |
| Sep 30, 2023 | 91.80 Mn |
| Jun 30, 2023 | 96.23 Mn |
| Mar 31, 2023 | 103.86 Mn |
| Dec 31, 2022 | 117.92 Mn |
| Sep 30, 2022 | 131.80 Mn |
| Jun 30, 2022 | 143.07 Mn |
| Mar 31, 2022 | 156.19 Mn |
| Dec 31, 2021 | 169.60 Mn |
| Sep 30, 2021 | 181.48 Mn |